Epilepsy is expected to be the fastest growing segment during the forecast period 2021–2028

According to a new market research study on “Asia Pacific Blood Brain Barrier Technologies Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology and Application,” is expected to reach US$ 1,123.04 million by 2028 from US$ 221.98 million in 2021. The market is estimated to grow at a CAGR of 26.1% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific blood brain barrier technologies market along with the drivers and restraints pertaining to the market growth. Growing demand of nanoparticles for brain drug delivery, huge number of product approvals and launches, and elevating prevalence of neurological disorders are the major factor driving the growth of the Asia Pacific blood brain barrier technologies market. However, concerns in brain medication delivery hinders the growth of Asia Pacific blood brain barrier technologies market.

As of September 2021, COVID-19 cases reached 56.5 million in Asia Pacific, according to the United Nations Office for the Coordination of Humanitarian Affairs (UNOCHA). COVID-19 also attacks the brain, which may result in a global or focal neurologic manifestation, according to few studies carried out in Asia. It has been reported that COVID-19 infection can also show several neurologic manifestations, such as ageusia, anosmia, or dysgeusia, and causes neurologic disorders such as stroke, encephalopathy, Guillain-Barre syndrome, and many more. Emerging evidence has revealed that SARS-CoV-2 can affect the central nervous system (CNS) in addition to the respiratory system. Scientists detected SARS-CoV-2 RNA in multiple organs, including post-mortem brain tissue of patients with COVID-19. A recent study of COVID-19 patients following an autopsy showed that SARS-CoV-2 was present in cortical neurons. In addition, the results from human brain organoids also illustrated the neuroinvasion capability of SARS-CoV-2. Together, these data provide evidence for SARS-CoV-2 infection in the human CNS, but how the virus invades the brain is still undiscovered. In few research studies, it has been observed the spike protein of the SARS-CoV-2 virus also crosses the blood brain barrier in several models. As a result, the blood-brain barrier technologies market in the region has seen significant expansion due to the COVID-19 impact.

The Asia Pacific blood brain barrier technologies market is segmented on the basis of technology, application, and country. Based on technology, the blood brain barrier technologies market is segmented into bispecific antibody RMT approach, trojan horse approach, increasing permeability, passive diffusion, and other non-invasive BBB technologies. In 2021, increasing permeability segment held the largest share in the market, and it is also expected to be the fastest growing segment during the forecast period. On the basis of application, the blood brain barrier technologies market is segmented into alzheimer’s disease, epilepsy, parkinson’s disease, multiple sclerosis, hunter’s syndrome, brain cancer, and others. In 2021, parkinson’s disease segment held the largest share in the market, and epilepsy is expected to be the fastest growing segment during the forecast period. Similarly, Based on country the market is segmented into China, Japan, India, Australia, South Korea, and Rest of APAC. In 2021, China held the largest share in the market, and India is expected to be the fastest growing country during the forecast period.

Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; Johnson & Johnson Services, Inc.; and JCR Pharmaceuticals Co., Ltd are among the leading companies in the Asia Pacific blood brain barrier technologies market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com